Phase Ii Study Of Nivolumab And Salvage Nivolumab Plus Ipilimumab In Treatment-Naive Patients (Pts) With Advanced Renal Cell Carcinoma (Rcc) (Hcrn Gu16-260).

Michael B. Atkins,Opeyemi Jegede,Naomi B. Haas,David F. McDermott,Mehmet Asim Bilen,Charles G. Drake,Jeffrey Alan Sosman,Robert S. Alter,Elizabeth R. Plimack,Brian I. Rini,Michael E. Hurwitz,David J. Peace,Sabina Signoretti,Catherine J. Wu,Paul J. Catalano,Hans J. Hammers

JOURNAL OF CLINICAL ONCOLOGY（2020）

引用 26|浏览16

暂无评分

摘要

5006Background: Nivolumab (nivo) is FDA approved for pts with VEGFR TKI-resistant RCC and the nivo + ipilimumab (nivo/ipi) combination is FDA approved for treatment naive pts with IMDC intermediate...

查看译文

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要